Orthocell Ltd (AU:OCC) has released an update.
Orthocell Ltd has reported a record-breaking quarter with a 14.41% increase in sales, reaching a quarterly revenue of $1.84 million and a yearly revenue of $6.72 million, marking a 30.40% surge from the previous year. These sales are driven by the success of their Striate+™ and Remplir™ products in the regenerative medicine market, with the company looking to expand into new markets supported by a strong cash position of $20.6 million. The global market for these products is estimated at over US$3 billion, indicating significant growth potential for Orthocell.
For further insights into AU:OCC stock, check out TipRanks’ Stock Analysis page.
